Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 122 participants.
Also called NCT02978040
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 122 participants
- Registry
-
NCT02978040
-
- Other papers using this trial's data
- Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial
- Prasugrel Intermediate Metabolite Modulates Platelet Inhibition by Negatively Interfering With an Active Metabolite: An Ex Vivo, In Vitro, and In Silico Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Italy, Switzerland
- Registry status
- Completed
Technical summary
Registry record NCT02978040. Randomized; single masking; primary purpose treatment. Start 2017-07-04 (actual); primary completion 2019-08-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.
- Acronym
- FABOLUS-FASTER
- Condition
- Coronary Artery Disease
- Condition
- STEMI - ST Elevation Myocardial Infarction
- Intervention (Drug)
- Cangrelor
- Intervention (Drug)
- Tirofiban
- Intervention (Drug)
- Prasugrel
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
Record details
- Record id
cardio:ct-nct02978040- Content hash
76c220bdfc36f8eac7d7435cf65042caae5a97bec7fbd76e58f81d868bb04499